Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949395 | 0.87 | TNK2 (0.60) | TNK2BTKLCKJAK3KDR | |
| SCHEMBL2952193 | 0.85 | TNK2 (0.64) | TNK2BTKLCKFGFR4JAK3 | |
| SCHEMBL4815958 | 0.81 | TNK2 (0.55) | TNK2STAT6BTKFGFR4JAK3 | |
| SCHEMBL3139892 | 0.78 | TNK2 (0.77) | TNK2BTKLCKJAK3CDK4 | |
| SCHEMBL30338621 | 0.78 | TNK2 (1.00) | TNK2STAT6BTKLCKJAK3 | |
| SCHEMBL2957964 | 0.77 | TNK2 (0.50) | TNK2BTKLCKJAK3KDR | |
| SCHEMBL2952192 | 0.77 | TNK2 (0.47) | TNK2JAK3JAK2PTK2CDK4 | |
| SCHEMBL2957977 | 0.75 | TNK2 (0.46) | TNK2FGFR4JAK3JAK2PTK2 | |
| SCHEMBL2956876 | 0.74 | TNK2 (0.69) | TNK2BTKLCKJAK3KDR | |
| SCHEMBL2949189 | 0.70 | TNK2 (0.46) | TNK2FGFR4CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | claimed |
| EP-1926734-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | Amgen Inc. (US) | 2008-06-04 | — | — | EP | claimed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885STAT6 667/4885BTK 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.